Kentaro Okamoto
Research Subjects
Kentaro Okamoto has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Hisahide Nishio
Faculty of Rehabilitation, Kobe Gakuin University, Kobe 651-2180, Japan
11 shared publications - Emma Tabe Eko Niba
Laboratory of Molecular and Biochemical Research, Biomedical Research Core Facilities, Juntendo University Graduate School of Medicine, Tokyo, Japan
10 shared publications - Hiroyuki Awano
Research Initiative Center, Organization for Research Initiative and Promotion, Tottori University, 86 Nishi-cho, Yonago 683-8503, Japan
10 shared publications - Toshio Saito
Department of Neurology, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama, Toyonaka 560-8552, Japan
10 shared publications - Yasuhiro Takeshima
Department of Pediatrics, School of Medicine, Hyogo Medical University, 1-1 Mukogawa, Nishinomiya 663-8501, Hyogo, Japan
10 shared publications - Masakazu Shinohara
Division of Molecular Epidemiology, The Integrated Center for Mass Spectrometry, Graduate School of Medicine, Kobe University, Kobe 650-0017, Hyogo, Japan
8 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (11) , 5134-5158
Survival Motor Neuron Protein Requirement–Supply Mismatch in Spinal Muscular Atrophy: A Conceptual Framework
- 10 August 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (11) , 5134-5158
Open AccessSurvival Motor Neuron Protein Requirement–Supply Mismatch in Spinal Muscular Atrophy: A Conceptual Framework
- Open Access
- 26 May 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (8) , 3351-3368
Disease-Modifying Therapies in Spinal Muscular Atrophy: Neurodevelopmental and Behavioral Outcomes in the Treatment Era
Spinal muscular atrophy (SMA) is a monogenic neuromuscular disorder caused by deficiency of the survival motor neuron (SMN) protein. Historically, SMA was regarded primarily as a disorder of lower motor neuron degeneration in which cognitive function was considered preserved. However, the advent of disease-modifying therapies (DMTs) has altered survival and motor outcomes, bringing cognitive, neurodevelopmental, and behavioral aspects of SMA into sharper clinical focus. This review re-examines cognitive and neurodevelopmental outcomes in SMA across historical and contemporary contexts, integrating pre-DMT clinical observations, mechanistic insights into SMN-dependent neurodevelopment, and emerging data from treated cohorts. Evidence from experimental models demonstrates that early SMN deficiency disrupts neural progenitor dynamics, synapse formation, circuit assembly, and neuron-glia interactions during critical developmental windows. These disturbances affect not only spinal motor circuits but also broader cortical and cerebellar networks, thereby conferring vulnerability to higher-order brain functions. Pre-DMT clinical studies reporting preserved cognition were shaped by survival bias, motor-dependent assessment tools, and limited evaluation of non-motor domains. In the DMT era, presymptomatic treatment has markedly improved developmental outcomes; nevertheless, cognitive, language, and behavioral phenotypes remain heterogeneous. Subtle vulnerabilities-particularly in expressive language, executive function, and social communication-are increasingly recognized, even among optimally treated individuals. These findings align with biological constraints imposed by developmental timing and limited plasticity of specific neural circuits. Assessment of neurodevelopmental outcomes in SMA is further complicated by motor confounding, reliance on proxy reports, and age- or severity-related limitations of existing tools, underscoring the need for motor-independent, domain-specific evaluation strategies. Collectively, current evidence supports reconceptualizing SMA in the DMT era as a neurodevelopmental condition characterized by persistent neurodevelopmental vulnerability, in which early intervention is necessary but not universally sufficient for complete normalization. Longitudinal follow-up, refined outcome measures, and trial designs incorporating non-motor endpoints are essential to capture the full impact of emerging therapies.
- 26 May 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (8) , 3351-3368
Open AccessDisease-Modifying Therapies in Spinal Muscular Atrophy: Neurodevelopmental and Behavioral Outcomes in the Treatment Era
Spinal muscular atrophy (SMA) is a monogenic neuromuscular disorder caused by deficiency of the survival motor neuron (SMN) protein. Historically, SMA was regarded primarily as a disorder of lower motor neuron degeneration in which cognitive function was considered preserved. However, the advent of disease-modifying therapies (DMTs) has altered survival and motor outcomes, bringing cognitive, neurodevelopmental, and behavioral aspects of SMA into sharper clinical focus. This review re-examines cognitive and neurodevelopmental outcomes in SMA across historical and contemporary contexts, integrating pre-DMT clinical observations, mechanistic insights into SMN-dependent neurodevelopment, and emerging data from treated cohorts. Evidence from experimental models demonstrates that early SMN deficiency disrupts neural progenitor dynamics, synapse formation, circuit assembly, and neuron-glia interactions during critical developmental windows. These disturbances affect not only spinal motor circuits but also broader cortical and cerebellar networks, thereby conferring vulnerability to higher-order brain functions. Pre-DMT clinical studies reporting preserved cognition were shaped by survival bias, motor-dependent assessment tools, and limited evaluation of non-motor domains. In the DMT era, presymptomatic treatment has markedly improved developmental outcomes; nevertheless, cognitive, language, and behavioral phenotypes remain heterogeneous. Subtle vulnerabilities-particularly in expressive language, executive function, and social communication-are increasingly recognized, even among optimally treated individuals. These findings align with biological constraints imposed by developmental timing and limited plasticity of specific neural circuits. Assessment of neurodevelopmental outcomes in SMA is further complicated by motor confounding, reliance on proxy reports, and age- or severity-related limitations of existing tools, underscoring the need for motor-independent, domain-specific evaluation strategies. Collectively, current evidence supports reconceptualizing SMA in the DMT era as a neurodevelopmental condition characterized by persistent neurodevelopmental vulnerability, in which early intervention is necessary but not universally sufficient for complete normalization. Longitudinal follow-up, refined outcome measures, and trial designs incorporating non-motor endpoints are essential to capture the full impact of emerging therapies.
- 30 January 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (3) , 701-703
Real-world treatment dynamics in spinal muscular atrophy: what the SMArtCARE registry renders visible
This scientific commentary refers to ‘Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registry’ by Voigt-Müller et al. (https://doi.org/10.1093/brain/awaf472).
- 30 January 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (3) , 701-703
Real-world treatment dynamics in spinal muscular atrophy: what the SMArtCARE registry renders visible
This scientific commentary refers to ‘Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registry’ by Voigt-Müller et al. (https://doi.org/10.1093/brain/awaf472).
- Open Access
Clinical and Genetic Profiles of 5q- and Non-5q-Spinal Muscular Atrophy Diseases in Pediatric Patients
Background: Spinal muscular atrophy (SMA) is a genetic disease characterized by loss of motor neurons in the spinal cord and lower brainstem. The term “SMA” usually refers to the most common form, 5q-SMA, which is caused by biallelic mutations in SMN1 (located on chromosome 5q13). However, long before the discovery of SMN1, it was known that other forms of SMA existed. Therefore, SMA is currently divided into two groups: 5q-SMA and non-5q-SMA. This is a simple and practical classification, and therapeutic drugs have only been developed for 5q-SMA (nusinersen, onasemnogene abeparvovec, risdiplam) and not for non-5q-SMA disease. Methods: We conducted a non-systematic critical review to identify the characteristics of each SMA disease. Results: Many of the non-5q-SMA diseases have similar symptoms, making DNA analysis of patients essential for accurate diagnosis. Currently, genetic analysis technology using next-generation sequencers is rapidly advancing, opening up the possibility of elucidating the pathology and treating non-5q-SMA. Conclusion: Based on accurate diagnosis and a deeper understanding of the pathology of each disease, treatments for non-5q-SMA diseases may be developed in the near future.
Open AccessClinical and Genetic Profiles of 5q- and Non-5q-Spinal Muscular Atrophy Diseases in Pediatric Patients
Background: Spinal muscular atrophy (SMA) is a genetic disease characterized by loss of motor neurons in the spinal cord and lower brainstem. The term “SMA” usually refers to the most common form, 5q-SMA, which is caused by biallelic mutations in SMN1 (located on chromosome 5q13). However, long before the discovery of SMN1, it was known that other forms of SMA existed. Therefore, SMA is currently divided into two groups: 5q-SMA and non-5q-SMA. This is a simple and practical classification, and therapeutic drugs have only been developed for 5q-SMA (nusinersen, onasemnogene abeparvovec, risdiplam) and not for non-5q-SMA disease. Methods: We conducted a non-systematic critical review to identify the characteristics of each SMA disease. Results: Many of the non-5q-SMA diseases have similar symptoms, making DNA analysis of patients essential for accurate diagnosis. Currently, genetic analysis technology using next-generation sequencers is rapidly advancing, opening up the possibility of elucidating the pathology and treating non-5q-SMA. Conclusion: Based on accurate diagnosis and a deeper understanding of the pathology of each disease, treatments for non-5q-SMA diseases may be developed in the near future.
- Top Cited PapersOpen Access
- 26 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (15) , 11939
Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment
Spinal muscular atrophy (SMA) is a lower motor neuron disease with autosomal recessive inheritance. The first cases of SMA were reported by Werdnig in 1891. Although the phenotypic variation of SMA led to controversy regarding the clinical entity of the disease, the genetic homogeneity of SMA was proved in 1990. Five years later, in 1995, the gene responsible for SMA, SMN1, was identified. Genetic testing of SMN1 has enabled precise epidemiological studies, revealing that SMA occurs in 1 of 10,000 to 20,000 live births and that more than 95% of affected patients are homozygous for SMN1 deletion. In 2016, nusinersen was the first drug approved for treatment of SMA in the United States. Two other drugs were subsequently approved: onasemnogene abeparvovec and risdiplam. Clinical trials with these drugs targeting patients with pre-symptomatic SMA (those who were diagnosed by genetic testing but showed no symptoms) revealed that such patients could achieve the milestones of independent sitting and/or walking. Following the great success of these trials, population-based newborn screening programs for SMA (more precisely, SMN1-deleted SMA) have been increasingly implemented worldwide. Early detection by newborn screening and early treatment with new drugs are expected to soon become the standards in the field of SMA.
- 26 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (15) , 11939
Top Cited PapersOpen AccessSpinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment
Spinal muscular atrophy (SMA) is a lower motor neuron disease with autosomal recessive inheritance. The first cases of SMA were reported by Werdnig in 1891. Although the phenotypic variation of SMA led to controversy regarding the clinical entity of the disease, the genetic homogeneity of SMA was proved in 1990. Five years later, in 1995, the gene responsible for SMA, SMN1, was identified. Genetic testing of SMN1 has enabled precise epidemiological studies, revealing that SMA occurs in 1 of 10,000 to 20,000 live births and that more than 95% of affected patients are homozygous for SMN1 deletion. In 2016, nusinersen was the first drug approved for treatment of SMA in the United States. Two other drugs were subsequently approved: onasemnogene abeparvovec and risdiplam. Clinical trials with these drugs targeting patients with pre-symptomatic SMA (those who were diagnosed by genetic testing but showed no symptoms) revealed that such patients could achieve the milestones of independent sitting and/or walking. Following the great success of these trials, population-based newborn screening programs for SMA (more precisely, SMN1-deleted SMA) have been increasingly implemented worldwide. Early detection by newborn screening and early treatment with new drugs are expected to soon become the standards in the field of SMA.
- Open Access
Correction: Noguchi et al. PCR-Based Screening of Spinal Muscular Atrophy for Newborn Infants in Hyogo Prefecture, Japan. Genes 2022, 13, 2110
The authors wish to make the following correction to this paper
Open AccessCorrection: Noguchi et al. PCR-Based Screening of Spinal Muscular Atrophy for Newborn Infants in Hyogo Prefecture, Japan. Genes 2022, 13, 2110
The authors wish to make the following correction to this paper
- Open Access
PCR-Based Screening of Spinal Muscular Atrophy for Newborn Infants in Hyogo Prefecture, Japan
Spinal muscular atrophy (SMA) is a common devastating neuromuscular disorder, usually involving homozygous deletion of the SMN1 gene. Newly developed drugs can improve the motor functions of infants with SMA when treated in the early stage. To ensure early diagnosis, newborn screening for SMA (SMA-NBS) via PCR-based genetic testing with dried blood spots (DBSs) has been spreading throughout Japan. In Hyogo Prefecture, we performed a pilot study of SMA-NBS to assess newborn infants who underwent routine newborn metabolic screening between February 2021 and August 2022. Hyogo Prefecture has ~40,000 live births per year and the estimated incidence of SMA is 1 in 20,000–25,000 based on genetic testing of symptomatic patients with SMA. Here, we screened 8336 newborns and 12 screen-positive cases were detected by real-time PCR assay. Multiplex ligation-dependent probe amplification assay excluded ten false positives and identified two patients. These false positives might be related to the use of heparinized and/or diluted blood in the DBS sample. Both patients carried two copies of SMN2, one was asymptomatic and the other was symptomatic at the time of diagnosis. SMA-NBS enables us to prevent delayed diagnosis of SMA, even if it does not always allow treatment in the pre-symptomatic stage.
Open AccessPCR-Based Screening of Spinal Muscular Atrophy for Newborn Infants in Hyogo Prefecture, Japan
Spinal muscular atrophy (SMA) is a common devastating neuromuscular disorder, usually involving homozygous deletion of the SMN1 gene. Newly developed drugs can improve the motor functions of infants with SMA when treated in the early stage. To ensure early diagnosis, newborn screening for SMA (SMA-NBS) via PCR-based genetic testing with dried blood spots (DBSs) has been spreading throughout Japan. In Hyogo Prefecture, we performed a pilot study of SMA-NBS to assess newborn infants who underwent routine newborn metabolic screening between February 2021 and August 2022. Hyogo Prefecture has ~40,000 live births per year and the estimated incidence of SMA is 1 in 20,000–25,000 based on genetic testing of symptomatic patients with SMA. Here, we screened 8336 newborns and 12 screen-positive cases were detected by real-time PCR assay. Multiplex ligation-dependent probe amplification assay excluded ten false positives and identified two patients. These false positives might be related to the use of heparinized and/or diluted blood in the DBS sample. Both patients carried two copies of SMN2, one was asymptomatic and the other was symptomatic at the time of diagnosis. SMA-NBS enables us to prevent delayed diagnosis of SMA, even if it does not always allow treatment in the pre-symptomatic stage.
- Open Access
- 26 September 2022
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 8 (4) , 52
Changes in the Incidence of Infantile Spinal Muscular Atrophy in Shikoku, Japan between 2011 and 2020
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder. Al-though there was no cure for SMA, newly developed therapeutic drugs (nusinersen, onasemnogene abeparvovec, and risdiplam) have been proven effective for the improvement of motor function and prevention of respiratory insufficiency of infants with SMA. Nusinersen was introduced in Japan in 2017 and onasemnogene abeparvovec in 2020. We hypothesized that the introduction of these drugs might influence the incidence of SMA (more precisely, increase the diagnosis rate of SMA) in Japan. To test this hypothesis, we conducted a second epidemiological study of infantile SMA using questionnaires in Shikoku, Japan between October 2021 and February 2022. The incidence of infantile SMA during the period 2016–2020 was 7.08 (95% confidence interval [CI] 2.45–11.71) per 100,000 live births. According to our previous epidemiological study, the incidence of infantile SMA during 2011–2015 was 2.70 (95% CI 0.05–5.35) per 100,000 live births. The increased incidence of infantile SMA suggests that the widespread news in Japan regarding the introduction of therapeutic agents, nusinersen and onasemnogene abeparvovec, raised clinicians’ awareness about SMA, leading to increased and earlier diagnosis of SMA in Shikoku.
- 26 September 2022
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 8 (4) , 52
Open AccessChanges in the Incidence of Infantile Spinal Muscular Atrophy in Shikoku, Japan between 2011 and 2020
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder. Al-though there was no cure for SMA, newly developed therapeutic drugs (nusinersen, onasemnogene abeparvovec, and risdiplam) have been proven effective for the improvement of motor function and prevention of respiratory insufficiency of infants with SMA. Nusinersen was introduced in Japan in 2017 and onasemnogene abeparvovec in 2020. We hypothesized that the introduction of these drugs might influence the incidence of SMA (more precisely, increase the diagnosis rate of SMA) in Japan. To test this hypothesis, we conducted a second epidemiological study of infantile SMA using questionnaires in Shikoku, Japan between October 2021 and February 2022. The incidence of infantile SMA during the period 2016–2020 was 7.08 (95% confidence interval [CI] 2.45–11.71) per 100,000 live births. According to our previous epidemiological study, the incidence of infantile SMA during 2011–2015 was 2.70 (95% CI 0.05–5.35) per 100,000 live births. The increased incidence of infantile SMA suggests that the widespread news in Japan regarding the introduction of therapeutic agents, nusinersen and onasemnogene abeparvovec, raised clinicians’ awareness about SMA, leading to increased and earlier diagnosis of SMA in Shikoku.
- Open Access
High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed SMN2 Splicing in Patient Fibroblasts
Spinal muscular atrophy (SMA) is caused by survival motor neuron 1 SMN1 deletion. The survival motor neuron 2 (SMN2) encodes the same protein as SMN1 does, but it has a splicing defect of exon 7. Some antisense oligonucleotides (ASOs) have been proven to correct this defect. One of these, nusinersen, is effective in SMA-affected infants, but not as much so in advanced-stage patients. Furthermore, the current regimen may exhibit a ceiling effect. To overcome these problems, high-dose ASOs or combined ASOs have been explored. Here, using SMA fibroblasts, we examined the effects of high-concentration ASOs and of combining two ASOs. Three ASOs were examined: one targeting intronic splicing suppressor site N1 (ISS-N1) in intron 7, and two others targeting the 3′ splice site and 5′ region of exon 8. In our experiments on all ASO types, a low or intermediate concentration (50 or 100 nM) showed better splicing efficiency than a high concentration (200 nM). In addition, a high concentration of each ASO created a cryptic exon in exon 6. When a mixture of two different ASOs (100 nM each) was added to the cells, the cryptic exon was included in the mRNA. In conclusion, ASOs at a high concentration or used in combination may show less splicing correction and cryptic exon creation.
Open AccessHigh Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed SMN2 Splicing in Patient Fibroblasts
Spinal muscular atrophy (SMA) is caused by survival motor neuron 1 SMN1 deletion. The survival motor neuron 2 (SMN2) encodes the same protein as SMN1 does, but it has a splicing defect of exon 7. Some antisense oligonucleotides (ASOs) have been proven to correct this defect. One of these, nusinersen, is effective in SMA-affected infants, but not as much so in advanced-stage patients. Furthermore, the current regimen may exhibit a ceiling effect. To overcome these problems, high-dose ASOs or combined ASOs have been explored. Here, using SMA fibroblasts, we examined the effects of high-concentration ASOs and of combining two ASOs. Three ASOs were examined: one targeting intronic splicing suppressor site N1 (ISS-N1) in intron 7, and two others targeting the 3′ splice site and 5′ region of exon 8. In our experiments on all ASO types, a low or intermediate concentration (50 or 100 nM) showed better splicing efficiency than a high concentration (200 nM). In addition, a high concentration of each ASO created a cryptic exon in exon 6. When a mixture of two different ASOs (100 nM each) was added to the cells, the cryptic exon was included in the mRNA. In conclusion, ASOs at a high concentration or used in combination may show less splicing correction and cryptic exon creation.
- Open Access
Stability and Oligomerization of Mutated SMN Protein Determine Clinical Severity of Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a common autosomal recessive neuromuscular disease characterized by defects of lower motor neurons. Approximately 95% of SMA patients are homozygous for survival motor neuron 1 (SMN1) gene deletion, while ~5% carry an intragenic SMN1 mutation. Here, we investigated the stability and oligomerization ability of mutated SMN1 proteins. Plasmids containing wild- and mutant-type SMN1 cDNA were constructed and transfected into HeLa cells. Reverse transcription-polymerase chain reaction (RT-PCR) demonstrated similar abundances of transcripts from the plasmids containing SMN cDNA, but Western blotting showed different expression levels of mutated SMN1 proteins, reflecting the degree of their instability. A mutated SMN1 protein with T274YfsX32 exhibited a much lower expression level than other mutated SMN1 proteins with E134K, Y276H, or Y277C. In immunoprecipitation analysis, the mutated SMN1 protein with T274YfsX32 did not bind to endogenous SMN1 protein in HeLa cells, suggesting that this mutation completely blocks the oligomerization with full-length SMN2 protein in the patient. The patient with T274YfsX32 showed a much more severe phenotype than the other patients with different mutations. In conclusion, the stability and oligomerization ability of mutated SMN1 protein may determine the protein stability and may be associated with the clinical severity of SMA caused by intragenic SMN1 mutation.
Open AccessStability and Oligomerization of Mutated SMN Protein Determine Clinical Severity of Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a common autosomal recessive neuromuscular disease characterized by defects of lower motor neurons. Approximately 95% of SMA patients are homozygous for survival motor neuron 1 (SMN1) gene deletion, while ~5% carry an intragenic SMN1 mutation. Here, we investigated the stability and oligomerization ability of mutated SMN1 proteins. Plasmids containing wild- and mutant-type SMN1 cDNA were constructed and transfected into HeLa cells. Reverse transcription-polymerase chain reaction (RT-PCR) demonstrated similar abundances of transcripts from the plasmids containing SMN cDNA, but Western blotting showed different expression levels of mutated SMN1 proteins, reflecting the degree of their instability. A mutated SMN1 protein with T274YfsX32 exhibited a much lower expression level than other mutated SMN1 proteins with E134K, Y276H, or Y277C. In immunoprecipitation analysis, the mutated SMN1 protein with T274YfsX32 did not bind to endogenous SMN1 protein in HeLa cells, suggesting that this mutation completely blocks the oligomerization with full-length SMN2 protein in the patient. The patient with T274YfsX32 showed a much more severe phenotype than the other patients with different mutations. In conclusion, the stability and oligomerization ability of mutated SMN1 protein may determine the protein stability and may be associated with the clinical severity of SMA caused by intragenic SMN1 mutation.